Using organoid models to study liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to develop patient-derived organoids (PDOs) from liver tissue to closely mimic the tumor microenvironment of hepatocellular carcinoma (HCC). The PDOs will be used to evaluate genomic and transcriptomic changes and their correlation with patient prognosis. Additionally, the study will test the efficacy of systemic therapies on these organoids, integrating patient-derived gut microbiota and immune cells to understand therapeutic responses. Advanced technologies such as next-generation sequencing and drug screening will be employed to enhance the understanding of treatment efficacy in HCC patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Capacity to express informed consent;
* Age ≥18 years;
* Suspected radiological diagnosis of HCC or diagnosis of HCC with indications for surgical resection.

Exclusion Criteria:

* Age \< 18 years;
* Contraindications to liver biopsy (ascites, platelets\<50,000, INR\>1.7);
* Contraindications to HCC resection surgery;
* Active viral infection;
* Refusal to sign informed consent to participate in the study.

Where it's running

• Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC CEMAD, Largo A. Gemelli, 8
  Roma, Italy Recruiting

Study contacts

• Principal investigator: Francesca Romana Ponziani, PI — Fondazione Policlinico A. Gemelli IRCCS, Rome, Largo A. Gemelli, 8
• Study coordinator: Francesca Romana Ponziani, PI
• Email: francescaromana.ponziani@policlinicogemelli.it
• Phone: 3471227242

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• InstaSure Non-Invasive Finger-Press Test for HCC

  This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.

  Recruiting Beijing Municipal Administration of Hospitals · Beijing, Beijing Municipality · NCT07848750

• Overnight Temperature Regulation to Test Gut Health, Inflammation, and Circadian Rhythms

  This study tests whether two weeks of using the Eight Sleep Pod at night can improve gut bacteria balance, lower inflammation, and strengthen daily temperature and blood pressure rhythms in postmenopausal women and age-matched men with poor sleep.

  Recruiting Eight Sleep Inc. · Newton Center, Massachusetts · NCT07848594

• BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer

  This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.

  Recruiting at 2 sites Phase 3 BeOne Medicines · South Brisbane, Queensland and 1 other locations · NCT07836530

• Zinc add-on with targeted therapy plus immunotherapy for advanced liver cancer

  This study tests whether adding daily zinc to standard targeted therapy and immunotherapy helps people with unresectable or advanced hepatocellular carcinoma.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07793695

• 68Ga-SorB PET/CT imaging for solid tumors

  This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07760012

• Hepatocellular Carcinoma Patient Registry (CHARM Hepatocellular Carcinoma MEA)

  This observational study collects medical records of adults with hepatocellular carcinoma to understand how the disease presents and progresses across regions in the Middle East and North Africa.

  Recruiting AstraZeneca · Al Mansurah and 16 other locations · NCT07650773

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.